OMZ delayed-release capsule

Ferron Par Pharmaceuticals

Ingredients in every delayed-release capsule

Omeprazole 20 mg

Each package contains

5 strips of 6 delayed-release capsule

Other details

Dosage form:Capsule delayed-release
Flavour: None

W.H.O. classification

ATC Level 1: A - Alimentary tract and metabolism
ATC Level 2: A02 - Drugs for Acid Related Disorders
ATC Level 3: A02A - Antacids



CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.


CAUTIONThis item may not be safe for use during lactation. Use with caution.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in


Dosage information

The recommended dose: 20 mg or 40 mg once daily swallowed whole with water.
• Patients with duodenal ulcer symptoms: treatment and healing may take 2 weeks. Patients who have not recovered within this initial treatment, usually require additional 2 weeks of therapy.

• Patients with peptic ulcers or erosive/ulcerative esophagitis reflux symptoms: treatment and healing may take 4 weeks. Patients who have not recovered usually require additional 4 weeks of treatment.

• Patients with refractory to other medications require 40 mg once daily and the healing usually attained within 4 weeks (for duodenal ulcer patients) or 8 weeks (for peptic ulcer or erosive/ulcerative esophagitis reflux).

• Patients with Zollinger-Ellison syndrome: initial dose is 20-160 mg once daily, the dose should be adjusted individually and treatment should be given as long as clinically indicated. Dose higher than 80 mg per day should be divided, twice daily.

Omeprazole capsule should be taken before meal.

The whole capsules should not be opened, chewed, or crushed and should be swallowed.

do not need special dose.

no dose adjustment is required for elderly patients.

there is no experience of the use of omeprazole in children.


– Short-term treatment of duodenal ulcers and which is unresponsive to H2 receptor antagonist drugs. (I p.3009, 3011; III p.3; IV p.O.17; VI p.2; VII; VIII p.4; IX p.13; X p.2210)

– Short-term treatment of peptic ulcers. (III p.3; IV p.O.17; V p.1; VI p.2; VII; VIII p.4; IX p.1; X p.2210)

– Treatment of erosive/ulcerative esophagitis reflux that has been diagnosed by endoscopy. (I p.3009, 3010; III p.3; IV p.O.17; V p.1, 2; VI p.2; VII; VIII p.4; IX p.13, 14; X p.2210)

– Long-term treatment of Zollinger-Ellison syndrome. (I p.3009, 3011; III p.3; IV p.O.17; V p.2; VI p.2; VII; VIII p.4; IX p.13)


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.